Short answer
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026, announced April 30, 2026.
Cartesian Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, announced April 30, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- Investor focus: cash position, operating expenses, pipeline progress, and liquidity outlook in the exhibit
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss widened to $39.2M, or $1.46 per share, from $17.7M, reflecting higher trial costs and contingent-value liability remeasurement
- Cash, equivalents and restricted cash totaled $120.4M, supporting planned operations through mid-2027, including AURORA completion
- $14.6M raised through the ATM in Q1, increasing financing flexibility but adding dilution risk as shares rose to 28.5M from 26.0M
- Phase 3 AURORA enrollment continued for approximately 100 MG patients, the lead value driver and pivotal test for Descartes-08
- Phase 2 TRITON began in myositis and multiple patients entered pediatric HELIOS, broadening the pipeline but increasing execution and funding demands
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cartesian Therapeutics, Inc. 8-K filings
Get the next RNAC 8-K as it lands
Follow RNAC for push alerts, or ask the research agent what this filing means.